MCID: NRF019
MIFTS: 73

Neurofibromatosis, Type 2 malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Ear diseases, Fetal diseases, Eye diseases, Cardiovascular diseases, Nephrological diseases, Skin diseases

Aliases & Classifications for Neurofibromatosis, Type 2

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 37MedGen, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Neurofibromatosis, Type 2:

Name: Neurofibromatosis, Type 2 52 12
Neurofibromatosis 2 23 24 25 70 27 39 68
Central Neurofibromatosis 11 23 24 25 54 70
Neurofibromatosis 1 11 23 24 25 39 68
Neurofibromatosis 11 48 49 50 38 13
Nf2 23 48 24 25 54 70
Bilateral Acoustic Neurofibromatosis 23 48 24 25 54
Neurofibromatosis Type Ii 71 23 48 24 25
Neurofibromatosis Type 1 11 48 25 50 13
Neurofibromatosis Type 2 11 48 25 54 50
Von Recklinghausen Disease 23 48 24 25
Nf1 23 48 24 25
Peripheral Neurofibromatosis 11 24 25
Von Recklinghausen's Neurofibromatosis 23 24
Neurofibromatosis Type Iv 11 27
Neurofibromatoses 39 68
Banf 24 25
Vestibular Schwannoma Neurofibromatosis 24
Neurofibromatosis, Type 4, of Riccardi 39
Type Iv Neurofibromatosis of Riccardi 11
 
Recklinghausen's Neurofibromatosis 11
Schwannoma, Acoustic, Bilateral 25
Acoustic Schwannomas, Bilateral 24
Neurofibromatosis Central Type 48
Acoustic Schwannomas Bilateral 48
Recklinghausen Disease, Nerve 25
Acoustic Neurinoma Bilateral 48
Von Recklinghausen's Disease 49
Acoustic Neurofibromatosis 11
Familial Acoustic Neuromas 25
Neurofibromatosis, Type Ii 52
Familial Acoustic Neuroma 68
Von Reklinghausen Disease 11
Type 1 Neurofibromatosis 48
Recklinghausen's Disease 48
Neurofibromatosis Type I 71
Neurofibromatosis Type 4 11
Nf 2 24
Nf 1 24

Characteristics:

Orphanet epidemiological data:

54
central neurofibromatosis:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Finland); Age of onset: All ages

HPO:

64
neurofibromatosis, type 2:
Inheritance: autosomal dominant inheritance
Inheritance: autosomal dominant inheritance, heterogeneous

GeneReviews:

23
Penetrance: penetrance is virtually complete after childhood...
Penetrance: penetrance is close to 100%. virtually all individuals who have a germline pathogenic variant develop the disease in an average lifetime...


Classifications:



External Ids:

OMIM52 101000
Disease Ontology11 DOID:8712
Orphanet54 ORPHA637
ICD10 via Orphanet31 Q85.0
MESH via Orphanet40 D009464, D016518
UMLS via Orphanet69 C0027832, C0027859

Summaries for Neurofibromatosis, Type 2

About this section
NINDS:49 The neurofibromatoses are genetic disorders that cause tumors to grow in the nervous system. The tumors begin in the supporting cells that make up the nerves and the myelin sheath--the thin membrane that envelops and protects the nerves. These disorders cause tumors to grow on nerves and, less frequently, in the brain and spinal cord, and produce other abnormalities such as skin changes and bone deformities. Although many affected persons inherit the disorder, between 30 and 50 percent of new cases arise spontaneously through mutation (change) in an individual's genes. Once this change has taken place, the mutant gene can be passed on to succeeding generations. There are three forms of neurofibromatosis (NF): NF1 is the more common type of the disorder. Symptoms of NF1, which may be evident at birth and nearly always by the time the child is 10 years old, may include light brown spots on the skin ("cafe-au-lait" spots), two or more growths on the iris of the eye, a tumor on the optic nerve, a larger than normal head circumference, and abnormal development of the spine, a skull bone, or the tibia. NF2 is less common and is characterized by slow-growing tumors on the vestibular branch of the right and left eighth cranial nerves, which are called vestibular schwannomas or acoustic neuromas.. The tumors press on and damage neighboring nerves and reduce hearing. The distinctive feature of schwannomatosis is the development of multiple schwannomas (tumors made up of certain cells) everywhere in the body except on the vestibular branch of the 8th cranial nerve. The dominant symptom is pain, which develops as a schwannoma enlarges or compresses nerves or adjacent tissue. Some people may develop numbness, tingling, or weakness in the fingers and toes.

MalaCards based summary: Neurofibromatosis, Type 2, also known as neurofibromatosis 2, is related to neurofibromatosis-noonan syndrome and plexiform schwannoma, and has symptoms including tinnitus, sensorineural hearing impairment and incoordination. An important gene associated with Neurofibromatosis, Type 2 is NF2 (Neurofibromin 2), and among its related pathways are pilocytic astrocytoma and Semaphorin Signaling. Affiliated tissues include brain, spinal cord and bone, and related mouse phenotypes are Increased cell migration and Decreased viability.

Genetics Home Reference:25 Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. The most common tumors associated with neurofibromatosis type 2 are called vestibular schwannomas or acoustic neuromas. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition.

NIH Rare Diseases:48 Neurofibromatosis (NF) is a genetic condition that causes tumors to develop in the nervous system. There are three types of neurofibromatosis that are each associated with unique signs and symptoms:Neurofibromatosis type 1 (NF1) causes skin changes (cafe-au-lait spots, freckling in armpit and groin area); bone abnormalities; optic gliomas; and tumors on the nerve tissue or under the skin. Signs and symptoms are usually present at birth. Neurofibromatosis type 2 (NF2) causes acoustic neuromas; hearing loss; ringing in the ears; poor balance; brain and/or spinal tumors; and cataracts at a young age. It often starts in the teen years. Schwannomatosis causes schwannomas, pain, numbness, and weakness. It is the rarest type. All three types of NF are inherited in an autosomal dominant manner. There is no cure for neurofibromatosis. Treatment is aimed at controlling symptoms and may include surgery to remove tumors, radiation therapy and/or medicines. Last updated: 7/27/2015

OMIM:52 The central or type II form of neurofibromatosis (NF2) is an autosomal dominant multiple neoplasia syndrome... (101000) more...

MedlinePlus:38 Neurofibromatosis is a genetic disorder of the nervous system. it mainly affects how nerve cells form and grow. it causes tumors to grow on nerves. you can get neurofibromatosis from your parents, or it can happen because of a mutation (change) in your genes. once you have it, you can pass it along to your children. usually the tumors are benign, but sometimes they can become cancerous. there are three types of neurofibromatosis: type 1 (nf1) causes skin changes and deformed bones. it usually starts in childhood. sometimes the symptoms are present at birth. type 2 (nf2) causes hearing loss, ringing in the ears, and poor balance. symptoms often start in the teen years. schwannomatosis causes intense pain. it is the rarest type. doctors diagnose the different types based on the symptoms. genetic testing is also used to diagnose nf1 and nf2. there is no cure. treatment can help control symptoms. depending on the type of disease and how serious it is, treatment may include surgery to remove tumors, radiation therapy, and medicines. nih: national institute of neurological disorders and stroke

UniProtKB/Swiss-Prot:70 Neurofibromatosis 2: Genetic disorder characterized by bilateral vestibular schwannomas (formerly called acoustic neuromas), schwannomas of other cranial and peripheral nerves, meningiomas, and ependymomas. It is inherited in an autosomal dominant fashion with full penetrance. Affected individuals generally develop symptoms of eighth-nerve dysfunction in early adulthood, including deafness and balance disorder. Although the tumors of NF2 are histologically benign, their anatomic location makes management difficult, and patients suffer great morbidity and mortality.

Wikipedia:71 Neurofibromatosis type II is a genetic condition which may be inherited or may arise spontaneously. The... more...

GeneReviews for NBK1109

GeneReviews for NBK1201

Related Diseases for Neurofibromatosis, Type 2

About this section

Diseases in the Neurofibromatosis, Type 2 family:

Neurofibromatosis, Type 1

Diseases related to Neurofibromatosis, Type 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 110)
idRelated DiseaseScoreTop Affiliating Genes
1neurofibromatosis-noonan syndrome31.9KIT, NF1, PMS2, RASA1, RASA2, SDHB
2plexiform schwannoma30.7NF1, NF2
3neurofibromatosis, type 112.4
4neurofibromatosis, familial spinal12.2
5legius syndrome12.0
6pediatric ependymoma10.9
7hemimegalencephaly10.8
8megalencephaly10.8
9meningococcemia10.7EZR, MSN
10watson syndrome10.7NF1, NF2
11gallbladder papillary carcinoma10.5EZR, MSN, NF2, RDX
12ovarian disease10.5NF1, NF2
13growth hormone insensitivity with immunodeficiency10.4NF1, PTPN11
14retinoschisis autosomal dominant10.4RET, SDHB, SDHD
15pancreatitis, pediatric10.4SDHC, SDHD
16conventional fibrosarcoma10.4NF1, NF2
17tropical spastic paraparesis10.4KIT, NF1, NF2
18ameloblastoma10.4RET, SDHB, SDHD
19demyelinating polyneuropathy10.4HRAS, RET
20schwannoma of twelfth cranial nerve10.4KIT, NF1, NF2
21peritoneal benign neoplasm10.4KIT, NF1, NF2
22relapsing epidemic typhus10.4KIT, PDGFRA
23vestibular gland benign neoplasm10.4KIT, NF1, NF2
24torticollis, familial10.4SDHB, SDHC, SDHD
25neuroendocrine carcinoma of the cervix10.3SDHB, SDHC, SDHD
26carcinoid tumors, intestinal10.3SDHB, SDHC, SDHD
27paraganglioma and gastric stromal sarcoma10.3SDHB, SDHC, SDHD
28male reproductive system disease10.3KIT, PDGFRA
29transverse colon cancer10.3PDGFRA, SDHB
30neonatal stroke10.3HRAS, NF1, PTPN11
31radioulnar synostosis10.3HRAS, NF1, PTPN11
32immunodeficiency, common variable, 510.3RET, SDHB, SDHD
33steroid-induced glaucoma10.3SDHB, SDHC, SDHD
34glycogen storage disease ib10.3SDHB, SDHC, SDHD
35vagina leiomyosarcoma10.3KIT, PDGFRA, SDHD
36lipoma of the rectum10.3SDHB, SDHC, SDHD
37sublingual gland adenoid cystic carcinoma10.3HRAS, KIT
38endocrine gland cancer10.2SDHB, SDHC, SDHD
39congenital disorder of glycosylation, type iq10.2KIT, PDGFRA
40adenosquamous carcinoma10.2HRAS, PDGFRA, RET
41epilepsy, familial focal, with variable foci10.2EZR, MSN, NF1, NF2, RDX, SLC9A3R1
42pilocytic astrocytoma of cerebellum10.2HRAS, NF1, PTPN11
43angiokeratoma circumscriptum10.2KIT, NF1, NF2, PDGFRA
44papillary ependymoma10.2EPB41L3, NF1, NF2
45chronic inflammatory demyelinating polyradiculoneuropathy10.2HRAS, RET
46seminal vesicle cystadenoma10.1RET, SDHB, SDHC, SDHD
47leopard syndrome 110.1HRAS, NF1, PTPN11, RASA2
48uterine corpus endometrial carcinoma10.1RET, SDHB, SDHC, SDHD
49localized osteosarcoma10.1HRAS, KIT, PDGFRA
50lung abscess10.1RET, SDHB, SDHC, SDHD

Graphical network of the top 20 diseases related to Neurofibromatosis, Type 2:



Diseases related to neurofibromatosis, type 2

Symptoms & Phenotypes for Neurofibromatosis, Type 2

About this section

Symptoms by clinical synopsis from OMIM:

101000

Clinical features from OMIM:

101000

Human phenotypes related to Neurofibromatosis, Type 2:

 64 54 (show all 42)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 tinnitus64 54 hallmark (90%) Very frequent (99-80%) HP:0000360
2 sensorineural hearing impairment64 54 hallmark (90%) Very frequent (99-80%) HP:0000407
3 incoordination64 hallmark (90%) HP:0002311
4 vertigo64 54 hallmark (90%) Very frequent (99-80%) HP:0002321
5 bilateral vestibular schwannoma64 85% HP:0009589
6 juvenile posterior subcapsular lenticular opacities64 72% HP:0007935
7 peripheral schwannoma64 68% HP:0009593
8 cataract64 54 typical (50%) Frequent (79-30%) HP:0000518
9 migraine64 54 typical (50%) Frequent (79-30%) HP:0002076
10 neoplasm of the skin64 54 typical (50%) Frequent (79-30%) HP:0008069
11 meningioma64 54 45% Occasional (29-5%) HP:0002858
12 cafe-au-lait spot64 43% HP:0000957
13 juvenile cortical cataract64 41% HP:0007876
14 hearing impairment64 35% HP:0000365
15 retinal hamartoma64 9% HP:0009594
16 ataxia64 54 8% Very frequent (99-80%) HP:0001251
17 visual impairment64 54 occasional (7.5%) Occasional (29-5%) HP:0000505
18 gait disturbance64 54 occasional (7.5%) Occasional (29-5%) HP:0001288
19 headache64 occasional (7.5%) HP:0002315
20 increased intracranial pressure64 54 occasional (7.5%) Occasional (29-5%) HP:0002516
21 opacification of the corneal stroma64 occasional (7.5%) HP:0007759
22 abnormality of the retinal vasculature64 54 occasional (7.5%) Occasional (29-5%) HP:0008046
23 glioma64 occasional (7.5%) HP:0009733
24 facial palsy64 54 occasional (7.5%) Occasional (29-5%) HP:0010628
25 unilateral vestibular schwannoma64 6% HP:0009590
26 astrocytoma64 54 4% Occasional (29-5%) HP:0009592
27 ependymoma64 2.5% HP:0002888
28 occasional neurofibromas64 54 Occasional (29-5%) HP:0009595
29 peripheral neuropathy64 HP:0009830
30 epiretinal membrane64 HP:0100014
31 atypical neurofibromatosis64 HP:0007524
32 lisch nodules64 HP:0009737
33 sensory neuropathy54 Occasional (29-5%)
34 subcutaneous nodule54 Occasional (29-5%)
35 cranial nerve paralysis54 Occasional (29-5%)
36 multiple cafe-au-lait spots54 Occasional (29-5%)
37 corneal opacity54 Occasional (29-5%)
38 pseudoepiphyses of the metacarpals54 Occasional (29-5%)
39 dysgraphia54 Occasional (29-5%)
40 neoplasm of the central nervous system54 Occasional (29-5%)
41 benign neoplasm of the central nervous system54 Occasional (29-5%)
42 papule54 Occasional (29-5%)

UMLS symptoms related to Neurofibromatosis, Type 2:


neuralgia, ataxia, headache, back pain, pain, sciatica, seizures, syncope, tremor, chronic pain, hyperexplexia, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Neurofibromatosis, Type 2 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00055-A-310.3HRAS, NF1, NF2, RDX
2GR00381-A-18.6HRAS, KIT, NF1, PDGFRA, RET, SDHD

MGI Mouse Phenotypes related to Neurofibromatosis, Type 2 according to GeneCards Suite gene sharing:

41 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.4KIT, NF1, NF2, PTPN11, RASA1, RDX
2MP:00053889.3HRAS, KIT, NF1, NF2, PDGFRA, PTPN11
3MP:00053808.8KIT, NF1, NF2, PDGFRA, PTPN11, RASA1
4MP:00030128.8HRAS, KIT, OMG, PDGFRA, PTPN11, RASA1
5MP:00053828.8HRAS, KIT, NF1, NF2, PDGFRA, PTPN11
6MP:00053678.6HRAS, KIT, NF1, NF2, PDGFRA, RET
7MP:00053898.3EPB41L3, KIT, NF2, PDGFRA, PMS2, PTPN11
8MP:00053868.3EPB41L3, HRAS, KIT, NF1, NF2, PDGFRA
9MP:00028738.1EPB41L3, HRAS, KIT, MSN, NF1, OMG
10MP:00053788.1EZR, HRAS, KIT, NF1, NF2, PDGFRA
11MP:00053858.0HRAS, KIT, NF1, PDGFRA, PTPN11, RASA1
12MP:00053798.0EPB41L3, HRAS, KIT, NF1, NF2, PDGFRA
13MP:00020067.9EPB41L3, HRAS, KIT, NF1, NF2, PDGFRA
14MP:00053817.7EZR, KIT, NF1, PDGFRA, PMS2, PTPN11
15MP:00036317.4EPB41L3, HRAS, KIT, NF1, NF2, PDGFRA
16MP:00053767.3HRAS, KIT, NF1, NF2, OMG, PDGFRA
17MP:00107686.6EPB41L3, EZR, HRAS, KIT, NF1, NF2

Drugs & Therapeutics for Neurofibromatosis, Type 2

About this section

Drugs for Neurofibromatosis, Type 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 185)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 1, Early Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
2
EverolimusapprovedPhase 4, Phase 2, Phase 1, Early Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
3
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 1, Early Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
4
PalbociclibapprovedPhase 4, Phase 2, Phase 1113571190-30-211431660, 5005498
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
 
EC-000.2350
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
S1116_Selleck
5
Sunitinibapproved, investigationalPhase 4, Phase 2500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
6
DopamineapprovedPhase 4375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
7
Sorafenibapproved, investigationalPhase 4, Phase 2, Phase 1692284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
8
Methylphenidateapproved, investigationalPhase 4373113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
9
Dasatinibapproved, investigationalPhase 4, Phase 2281302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
10
CrizotinibapprovedPhase 4, Phase 297877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
11
TrametinibapprovedPhase 4, Phase 2, Phase 1121871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
12
OlaparibapprovedPhase 4126763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
13
Gefitinibapproved, investigationalPhase 4351184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
14
Ramucirumabapproved, investigationalPhase 474947687-13-0
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
15
Vorinostatapproved, investigationalPhase 4242149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
16
CeritinibapprovedPhase 4361032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib
17
Bortezomibapproved, investigationalPhase 4794179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
18
Lapatinibapproved, investigational, Approved March 2007Phase 4, Phase 2, Early Phase 1296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
19Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110884
20Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16972
21Protein Kinase InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13612
22Antifungal AgentsPhase 4, Phase 2, Phase 1, Early Phase 13615
23Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
24Immunosuppressive AgentsPhase 4, Phase 2, Phase 1, Early Phase 112770
25Dopamine AgentsPhase 43759
26Neurotransmitter Uptake InhibitorsPhase 43464
27Central Nervous System StimulantsPhase 42132
28Dopamine Uptake InhibitorsPhase 41305
29
Erlotinib HydrochloridePhase 4, Phase 2, Phase 1798183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
30Imatinib MesylatePhase 4, Phase 2, Phase 3, Phase 1594123596
31Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 117734
32Poly(ADP-ribose) Polymerase InhibitorsPhase 4309
33
MechlorethamineapprovedPhase 3, Phase 237751-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
34
IfosfamideapprovedPhase 3, Phase 23913778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide (JAN/USP/INN)
 
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
35
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
36
Minocyclineapproved, investigationalPhase 322410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
37
Tamsulosinapproved, investigationalPhase 3, Phase 1157106133-20-4129211
Synonyms:
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
106133-20-4
5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
AC1L2V76
BIDD:GT0261
C07124
C20H28N2O5S
CHEBI:9398
CHEMBL836
CID129211
D08560
DB00706
FT-0082894
Flomax
Flomax (TN)
 
Flowmax
HMS2090P15
Harnal
LS-31578
MolPort-003-850-388
NCGC00167442-01
STK626950
TAMSULOSIN
Tamsolusin
Tamsulon
Tamsulon (TN)
Tamsulosin
Tamsulosin (INN)
Tamsulosin [INN:BAN]
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
UNII-G3P28OML5I
YM-617
38
Lamotrigineapproved, investigationalPhase 2, Phase 318384057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
39
Cyclophosphamideapproved, investigationalPhase 2, Phase 3282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
40
Chlorhexidineapproved, vet_approvedPhase 2, Phase 347255-56-19552079, 2713
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
CID9552079
Chlorhexidin
Chlorhexidin [Czech]
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine Base
Chlorhexidine [INN:BAN]
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
HMS1568M08
HSDB 7196
Hexadol
Hibiclens
Hibispray
Hibistat
I06-0621
I14-0050
IDI1_000761
 
KBio1_000761
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
LS-43917
Lisium (*Dihydrochloride*)
MK-412A
MLS001332387
MLS001332388
MLS002154209
Merfen-incolore
Merfen-incolore (TN)
MolPort-002-541-741
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
NSC526936
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
Oro-Clense
Peridex
Periogard
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
Prestwick_53
QTL1_000020
Rotersept
SMR000857146
SPBio_000210
SPBio_002185
STK089248
STOCK1S-18831
Savloclens
Savlon babycare
Sebidin A
Sodium Houttuyfonamide
Soretol
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Spectrum_000237
Sterido
Sterilon
Superspray
Tubulicid
UNII-R4KO0DY52L
chlorhexidine
41
DoxilApproved June 1999Phase 3, Phase 2, Phase 1171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
42Alkylating AgentsPhase 3, Phase 24694
43Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14945
44Isophosphamide mustardPhase 3, Phase 2391
45Antineoplastic Agents, AlkylatingPhase 3, Phase 24474
46calcium channel blockersPhase 2, Phase 3, Phase 11940
47Calcium, DietaryPhase 2, Phase 3, Phase 15525
48Adrenergic alpha-AntagonistsPhase 3, Phase 1727
49AnticonvulsantsPhase 2, Phase 3, Phase 12620
50Adrenergic AntagonistsPhase 3, Phase 11535

Interventional clinical trials:

(show top 50)    (show all 184)
idNameStatusNCT IDPhase
1NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by MethylphenidateCompletedNCT00169611Phase 4
2Stereotactic Body Radiotherapy for Spine TumorsActive, not recruitingNCT01347307Phase 4
3Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaNot yet recruitingNCT02645149Phase 4
4First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous NeurofibromasUnknown statusNCT00921037Phase 2, Phase 3
5Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaUnknown statusNCT00346164Phase 3
6Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTSCompletedNCT02303769Phase 3
7Minocycline in Clinically Isolated Syndromes (CIS)CompletedNCT00666887Phase 3
8Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic PainRecruitingNCT02471339Phase 3
9Effect of Lamotrigine on Cognition in NF1RecruitingNCT02256124Phase 2, Phase 3
10Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryRecruitingNCT02180867Phase 2, Phase 3
11Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath TumorsTerminatedNCT00427583Phase 2, Phase 3
12A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform NeurofibromasUnknown statusNCT00634270Phase 2
13Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1CompletedNCT00754780Phase 2
14Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232TCompletedNCT02332902Phase 2
15Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2CompletedNCT01419639Phase 2
16Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform NeurofibromasCompletedNCT00030264Phase 2
17Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform NeurofibromasCompletedNCT01412892Phase 2
18Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform NeurofibromasCompletedNCT00076102Phase 2
19R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform NeurofibromasCompletedNCT00021541Phase 2
20Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01673009Phase 2
21Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT00973739Phase 2
22Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)CompletedNCT01207687Phase 2
23Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT02104323Phase 2
24Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2CompletedNCT00004437Phase 2
25Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath TumorsCompletedNCT00304083Phase 2
26Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable MeningiomaCompletedNCT00589784Phase 2
27S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorCompletedNCT00068367Phase 2
28Sorafenib and Dacarbazine in Soft Tissue SarcomaCompletedNCT00837148Phase 2
29Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
30Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaCompletedNCT00245102Phase 2
31Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict SensitivityCompletedNCT01024946Phase 2
32Photodynamic Therapy for Benign Dermal NeurofibromasRecruitingNCT02728388Phase 2
33Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasRecruitingNCT02129647Phase 2
34Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by SurgeryRecruitingNCT02407405Phase 2
35Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasRecruitingNCT02177825Phase 2
36Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsRecruitingNCT02934256Phase 2
37Study of RAD001 for Treatment of NF2-related Vestibular SchwannomaRecruitingNCT01345136Phase 2
38PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)RecruitingNCT02390752Phase 1, Phase 2
39AZD2014 In NF2 Patients With Progressive or Symptomatic MeningiomasRecruitingNCT02831257Phase 2
40Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular SchwannomasRecruitingNCT01767792Phase 2
41AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsRecruitingNCT01362803Phase 1, Phase 2
42A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)RecruitingNCT02718131Phase 2
43Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated TumorsRecruitingNCT02285439Phase 1, Phase 2
44Multisession Radiosurgery for Optic Nerve Sheath MeningiomasRecruitingNCT02594709Phase 2
45A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative SurgeryRecruitingNCT02691026Phase 2
46PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT02584647Phase 1, Phase 2
47Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue SarcomaRecruitingNCT02584309Phase 2
48Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
49Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue SarcomaRecruitingNCT01532687Phase 2
50Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsRecruitingNCT02352844Phase 2

Search NIH Clinical Center for Neurofibromatosis, Type 2


Cochrane evidence based reviews: neurofibromatoses

Genetic Tests for Neurofibromatosis, Type 2

About this section

Genetic tests related to Neurofibromatosis, Type 2:

id Genetic test Affiliating Genes
1 Neurofibromatosis, Type 227
2 Neurofibromatosis Type 427
3 Neurofibromatosis 224 NF2

Anatomical Context for Neurofibromatosis, Type 2

About this section

MalaCards organs/tissues related to Neurofibromatosis, Type 2:

36
Brain, Spinal cord, Bone, Skin, Eye, Testes, Pancreas

Publications for Neurofibromatosis, Type 2

About this section

Articles related to Neurofibromatosis, Type 2:

(show top 50)    (show all 149)
idTitleAuthorsYear
1
Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. (27856782)
2017
2
Neurofibromatosis Type 2: Presentation, Major Complications, and Management, With a Focus on the Pediatric Age Group. (27655473)
2016
3
Growth dynamics of intramedullary spinal tumors in patients with neurofibromatosis type 2. (27208873)
2016
4
Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review. (27123050)
2016
5
Neurofibromatosis type 2 (NF 2) or schwannomatosis? - Case report study and diagnostic criteria. (27154453)
2016
6
Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2. (27146400)
2016
7
Multifocal granulocytic sarcoma of the spine mimicking neurofibromatosis Type 2: case report. (27176110)
2016
8
Erratum: Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. (27231815)
2016
9
YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX2-EGFR signaling axis. (27216189)
2016
10
Gastric plexiform schwannoma in association with neurofibromatosis type 2. (27696205)
2016
11
Cilioretinal Artery Territory Infarction Associated With Papilledema in a Patient With Neurofibromatosis Type 2. (26295608)
2015
12
Combined Hamartoma of the Retina and Retinal Pigment Epithelium Leading to the Diagnosis of Neurofibromatosis Type 2. (26356002)
2015
13
Commentary on: 'Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: A case control study'. (26070489)
2015
14
Primary meningeal melanoma with cerebrospinal fluid dissemination mimicking neurofibromatosis type 2. (26200063)
2015
15
Intractable yawning caused by foramen magnum meningioma in a patient with neurofibromatosis type 2. (25751482)
2015
16
Leptomeningeal Angiomatosis in a Case of Neurofibromatosis Type 2: An Unusual Finding. (26510155)
2015
17
Neurosurgery Concepts: Key perspectives on quality of life in children with spina bifida, cilengitide for the treatment of newly diagnosed glioblastoma, surgery and stereotactic radiosurgery in the management of intracranial metastasis, Gamma Knife radiosurgery in patients with Neurofibromatosis Type 2, patient misconceptions on the diagnosis and treatment of lumbar spondylosis. (26167362)
2015
18
Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. (26407091)
2015
19
Neurofibromatosis type 2 patient presenting with medulloblastoma. (26539318)
2015
20
Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: A case control study. (26139580)
2015
21
Neurofibromatosis type 2. (26564072)
2015
22
A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. (25360213)
2014
23
A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma. (25406210)
2014
24
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. (24311643)
2014
25
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. (24335938)
2014
26
Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes. (25549701)
2014
27
Spinal tanycytic ependymoma associated with neurofibromatosis type 2. (24495349)
2014
28
In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. (24336196)
2014
29
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. (24414536)
2014
30
Characterization of early onset neurofibromatosis type 2. (23414620)
2014
31
Translabyrinthine resection of neurofibromatosis type 2 associated vestibular and facial schwannomas, repair of facial nerve, and placement of auditory brainstem implant. (24380525)
2014
32
Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2. (24335931)
2014
33
Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. (24961548)
2014
34
Co-existence of neurofibromatosis type 2 and multiple sclerosis: A case report. (25876477)
2014
35
Neurofibromatosis type 2 in the elderly population: clinical and molecular features. (23322716)
2013
36
Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma. (23308224)
2013
37
LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. (23934191)
2013
38
Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. (23407292)
2013
39
Hepatic angiomyolipoma and neurofibromatosis type 2: a novel association. (24314304)
2013
40
Natural history of neurofibromatosis type 2 with onset before the age of 1A year. (23377185)
2013
41
An uncommon case of neurofibromatosis type 2: a tribute to the intracranial calcifications. (23814693)
2013
42
Genomic analysis of non-neurofibromatosis type 2 meningiomas. (23685513)
2013
43
Schwannomatosis/neurofibromatosis type 2 associated multiple schwannomas visualized on FDG-PET/CT. (23582492)
2013
44
Correction: Neurofibromatosis Type 2 Tumor Suppressor Protein, NF2, Induces Proteasome-Mediated Degradation of JC Virus T-Antigen in Human Glioblastoma. (24137515)
2013
45
Imatinib in neurofibromatosis type 2. (23839611)
2013
46
Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator. (23267122)
2013
47
Intracranial meningiomas and neurofibromatosis type 2. (23558725)
2013
48
Understanding neurofibromatosis type 2. (24427892)
2013
49
English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2. (24136318)
2013
50
Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. (23381342)
2013

Variations for Neurofibromatosis, Type 2

About this section

UniProtKB/Swiss-Prot genetic disease variations for Neurofibromatosis, Type 2:

70 (show all 16)
id Symbol AA change Variation ID SNP ID
1NF2p.Phe62SerVAR_000810rs121434261
2NF2p.Glu106GlyVAR_000813
3NF2p.Asn220TyrVAR_000818
4NF2p.Thr352MetVAR_000821rs764441073
5NF2p.Leu360ProVAR_000822rs74315492
6NF2p.Leu535ProVAR_000825rs74315493
7NF2p.Gln538ProVAR_000826rs74315494
8NF2p.Leu234ArgVAR_009123
9NF2p.Met77ValVAR_043011
10NF2p.Leu141ProVAR_043012
11NF2p.Gly197CysVAR_043013
12NF2p.Lys413GluVAR_043014rs766974263
13NF2p.Lys533ThrVAR_043015
14NF2p.Leu539HisVAR_043016
15NF2p.Lys579MetVAR_043017
16NF2p.Cys133ArgVAR_065227

Clinvar genetic disease variations for Neurofibromatosis, Type 2:

5 (show all 196)
id Gene Variation Type Significance SNP ID Assembly Location
1NF1NM_001042492.2(NF1): c.2033dupC (p.Ile679Aspfs)duplicationPathogenicrs587781807GRCh37Chr 17, 29553484: 29553484
2NF1NM_001042492.2(NF1): c.7909C> T (p.Arg2637Ter)SNVLikely pathogenic, Pathogenicrs786201367GRCh37Chr 17, 29684326: 29684326
3NF1NM_001042492.2(NF1): c.6855C> A (p.Tyr2285Ter)SNVPathogenicrs772295894GRCh37Chr 17, 29665757: 29665757
4NF1NM_001042492.2(NF1): c.5609G> A (p.Arg1870Gln)SNVPathogenicrs786202112GRCh37Chr 17, 29654857: 29654857
5NF1NM_001042492.2(NF1): c.3457_3460delCTCA (p.Leu1153Metfs)deletionPathogenicrs786202594GRCh37Chr 17, 29559860: 29559863
6NF1NM_001042492.2(NF1): c.625C> T (p.Gln209Ter)SNVPathogenicrs786203448GRCh37Chr 17, 29508478: 29508478
7NF1NM_000267.3(NF1): c.1782_1783delAG (p.Glu595Asnfs)deletionPathogenicrs786204059GRCh38Chr 17, 31223504: 31223505
8NF1NM_000267.3(NF1): c.2294_2300delGCATTGA (p.Glu767Profs)deletionPathogenicrs786204154GRCh37Chr 17, 29554278: 29554284
9NF1NM_000267.3(NF1): c.2041C> T (p.Arg681Ter)SNVPathogenicrs768638173GRCh38Chr 17, 31226474: 31226474
10NF1NM_000267.3(NF1): c.3494T> A (p.Ile1165Lys)SNVPathogenicrs786204211GRCh38Chr 17, 31232879: 31232879
11NF1NM_000267.3(NF1): c.3500T> G (p.Leu1167Ter)SNVPathogenicrs786204253GRCh37Chr 17, 29560023: 29560023
12NF1NM_000267.3(NF1): c.1733dupT (p.Tyr580Leufs)duplicationPathogenicrs786204255GRCh37Chr 17, 29550473: 29550473
13NF1NM_000267.3(NF1): c.5425C> T (p.Arg1809Cys)SNVPathogenicrs797045139GRCh37Chr 17, 29654736: 29654736
14NF1NM_000267.3(NF1): c.5426G> T (p.Arg1809Leu)SNVPathogenicrs771529172GRCh37Chr 17, 29654737: 29654737
15NF1NM_000267.3(NF1): c.5426G> C (p.Arg1809Pro)SNVPathogenicrs771529172GRCh37Chr 17, 29654737: 29654737
16NF1NM_000267.3(NF1): c.5425C> A (p.Arg1809Ser)SNVPathogenicrs797045139GRCh37Chr 17, 29654736: 29654736
17NF1NM_000267.3(NF1): c.5425C> G (p.Arg1809Gly)SNVPathogenicrs797045139GRCh37Chr 17, 29654736: 29654736
18NF1NM_000267.3(NF1): c.1058delT (p.Lys354Argfs)deletionPathogenicrs863224488GRCh38Chr 17, 31200591: 31200591
19NF1NM_000267.3(NF1): c.1713G> A (p.Trp571Ter)SNVPathogenicrs863224489GRCh37Chr 17, 29548939: 29548939
20NF1NM_000267.3(NF1): c.3113+1G> TSNVPathogenicrs267606599GRCh38Chr 17, 31230383: 31230383
21NF1NM_000267.3(NF1): c.3138_3139delAG (p.Asp1047Leufs)deletionPathogenicrs863224490GRCh38Chr 17, 31230866: 31230867
22NF1NM_000267.3(NF1): c.4483G> T (p.Glu1495Ter)SNVPathogenicrs786203390GRCh37Chr 17, 29587502: 29587502
23NF1NM_000267.3(NF1): c.5749+332A> GSNVPathogenicrs863224491GRCh38Chr 17, 31330830: 31330830
24NF1NM_000267.3(NF1): c.6999+1G> ASNVPathogenicrs863224492GRCh38Chr 17, 31340646: 31340646
25NF1NM_000267.3(NF1): c.7419G> A (p.Trp2473Ter)SNVPathogenicrs863224493GRCh38Chr 17, 31352281: 31352281
26NF1NM_000267.3(NF1): c.5844_5845delAA (p.Arg1949Serfs)deletionPathogenicrs863224835GRCh38Chr 17, 31334932: 31334933
27NF1NM_000267.3(NF1): c.6789_6792delTTAC (p.Tyr2264Thrfs)deletionPathogenicrs863224836GRCh37Chr 17, 29665754: 29665757
28NF1NM_000267.3(NF1): c.7734dupT (p.Glu2579Terfs)duplicationPathogenicrs863224837GRCh37Chr 17, 29684036: 29684036
29NF1NM_000267.3(NF1): c.61-5189_205-1285deldeletionPathogenicGRCh38Chr 17, 31150794: 31157725
30NF1NM_000267.3(NF1): c.61-12088_204+933deldeletionPathogenicGRCh37Chr 17, 29470913: 29484077
31NF1NM_000267.3(NF1): c.61-16315_479+99deldeletionPathogenicGRCh37Chr 17, 29466686: 29490493
32NF1NM_000267.3(NF1): c.60+24136_587-5022deldeletionPathogenicChr na, -1: -1
33NF1NM_000267.3(NF1): c.60+3120_3975-326deldeletionPathogenicChr na, -1: -1
34NF1NM_000267.3(NF1): c.205-1284_289-944deldeletionPathogenicGRCh37Chr 17, 29484744: 29489260
35NF1NM_000267.3(NF1): c.204+155_2990+53deldeletionPathogenicChr na, -1: -1
36NF1NM_000267.3(NF1): c.288+230_480-1812delins323indelPathogenicGRCh37Chr 17, 29486341: 29495097
37NF1NM_000267.3(NF1): c.289-956_586+4999deldeletionPathogenicGRCh37Chr 17, 29489248: 29502014
38NF1NM_000267.3(NF1): c.289-950_586+3043deldeletionPathogenicGRCh38Chr 17, 31162236: 31173040
39NF1NM_000267.3(NF1): c.289-1237_586+3325deldeletionPathogenicGRCh37Chr 17, 29488967: 29500340
40NF1NM_000267.3(NF1): c.480-2989_586+3445deldeletionPathogenicGRCh37Chr 17, 29493920: 29500460
41NF1NM_000267.3(NF1): c.480-2832_888+5938delinsTTGAAindelPathogenicGRCh37Chr 17, 29494077: 29515621
42NF1NM_000267.3(NF1): c.480-134_8315-6206deldeletionPathogenicChr na, -1: -1
43NF1NM_000267.3(NF1): c.587-1766_888+1856deldeletionPathogenicGRCh37Chr 17, 29506674: 29511539
44NF1NM_000267.3(NF1): c.586+2095_1261-2276delinsGTGGindelPathogenicGRCh37Chr 17, 29499110: 29530982
45NF1NM_000267.3(NF1): c.586+3099_1261-1045deldeletionPathogenicGRCh37Chr 17, 29500114: 29532213
46NF1NM_000267.3(NF1): c.586+1209_1845+35deldeletionPathogenicChr na, -1: -1
47NF1NM_000267.3(NF1): c.587-282_8315-3687deldeletionPathogenicChr na, -1: -1
48NF1NM_000267.3(NF1): c.655-60_888+5621delins135indelPathogenicGRCh37Chr 17, 29508668: 29515304
49NF1NM_000267.3(NF1): c.731-302_8314+3681deldeletionPathogenicChr na, -1: -1
50NF1NM_000267.3(NF1): c.889-453_908deldeletionPathogenicGRCh38Chr 17, 31199969: 31200441
51NF1NM_000267.3(NF1): c.888+5515_1261-1635deldeletionPathogenicGRCh37Chr 17, 29515198: 29531623
52NF1NM_000267.3(NF1): c.889-8107_1261-278deldeletionPathogenicGRCh38Chr 17, 31192315: 31205962
53NF1NM_000267.3(NF1): c.889-894_1261-284deldeletionPathogenicGRCh37Chr 17, 29526546: 29532974
54NF1NM_000267.3(NF1): c.888+8334_1721+34delinsTCindelPathogenicGRCh37Chr 17, 29518017: 29548981
55NF1NM_000267.3(NF1): c.888+3798_5750-2053deldeletionPathogenicChr na, -1: -1
56NF1NM_000267.3(NF1): c.889-8381_6757-5deldeletionPathogenicChr na, -1: -1
57NF1NM_000267.3(NF1): c.889-1633_7395-667deldeletionPathogenicChr na, -1: -1
58NF1NM_000267.3(NF1): c.1260+220_7553-1095deldeletionPathogenicChr na, -1: -1
59NF1NM_000267.3(NF1): c.1393-2652_1528-892deldeletionPathogenicGRCh37Chr 17, 29538817: 29545131
60NF1NM_000267.3(NF1): c.1393-2488_1642-648delinsAATAGindelPathogenicGRCh38Chr 17, 31211963: 31221202
61NF1NM_000267.3(NF1): c.1393-3329_3975-6377deldeletionPathogenicGRCh37Chr 17, 29538140: 29569625
62NF1NM_000267.3(NF1): c.1527+1509_1641+1137deldeletionPathogenicGRCh37Chr 17, 29543112: 29547273
63NF1NM_000267.3(NF1): c.1528-960_1761deldeletionPathogenicGRCh37Chr 17, 29545063: 29550501
64NF1NM_000267.3(NF1): c.1641+156_3975-2222deldeletionPathogenicGRCh37Chr 17, 29546292: 29573780
65NF1NM_000267.3(NF1): c.1846-496_2410-645delinsTAGCindelPathogenicGRCh37Chr 17, 29551617: 29555398
66NF1NM_000267.3(NF1): c.1988_2410-218delinsTGTCindelPathogenicGRCh38Chr 17, 31225237: 31228807
67NF1NM_000267.3(NF1): c.1845+537_4661+331deldeletionPathogenicGRCh37Chr 17, 29551122: 29589206
68NF1NM_000267.3(NF1): c.1846-613_4773-1009delinsTTAGGTTTATindelPathogenicChr na, -1: -1
69NF1NM_000267.3(NF1): c.2048_5041deldeletionPathogenicChr na, -1: -1
70NF1NM_000267.3(NF1): c.2410-110_2850+65delinsAAAAindelPathogenicGRCh37Chr 17, 29555933: 29556548
71NF1NM_000267.3(NF1): c.3709-941_3974+2711deldeletionPathogenicGRCh37Chr 17, 29561688: 29565750
72NF1NM_000267.3(NF1): c.3708+598_4772+16224deldeletionPathogenicGRCh37Chr 17, 29560829: 29608581
73NF1NM_000267.3(NF1): c.3709-266_7259-397delinsCAGindelPathogenicChr na, -1: -1
74NF1NM_000267.3: c.3975-1046_4110+902deins333insertionPathogenicChr na, -1: -1
75NF1NM_000267.3(NF1): c.3975-1922_4111-2448delinsTTTACTTAGGTindelPathogenicGRCh37Chr 17, 29574080: 29582914
76NF1NM_000267.3: c.3975-364_4515-510indel810deletionPathogenicChr na, -1: -1
77NF1NM_000267.3(NF1): c.4368-391_4515-122delins105indelPathogenicGRCh37Chr 17, 29586996: 29588607
78NF1NM_000267.3(NF1): c.4662-1076_4772+1300delins260indelPathogenicGRCh37Chr 17, 29591171: 29593657
79NF1NM_000267.3(NF1): c.4662-397_4773-14262deldeletionPathogenicGRCh37Chr 17, 29591850: 29638576
80NF1NM_000267.3(NF1): c.4661+1660_4773-8837deldeletionPathogenicChr na, -1: -1
81NF1NM_000267.3(NF1): c.4515-343_8314+3380deldeletionPathogenicChr na, -1: -1
82NF1NM_000267.3(NF1): c.4773-22561_6311deldeletionPathogenicGRCh37Chr 17, 29630277: 29663879
83NF1NM_000267.3(NF1): c.4773-2116_7127-1817delinsAGTTACCindelPathogenicGRCh37Chr 17, 29650722: 29674321
84NF1NM_000267.3(NF1): c.4941_7127-2901deldeletionPathogenicGRCh37Chr 17, 29653006: 29673237
85NF1NM_000267.3(NF1): c.4773-23713_7907+14deldeletionPathogenicChr na, -1: -1
86NF1NM_000267.3(NF1): c.5546+336_5943+244deldeletionPathogenicGRCh38Chr 17, 31328175: 31335275
87NF1NM_000267.3: c.5547-961+5943+244deldeletionPathogenicChr na, -1: -1
88NF1NM_000267.3(NF1): c.5750-460_5943+244deldeletionPathogenicGRCh37Chr 17, 29661396: 29662293
89NF1NM_000267.3(NF1): c.5749+750_5943+244deldeletionPathogenicGRCh37Chr 17, 29658266: 29662293
90NF1NM_000267.3(NF1): c.5750-1086_5943+244deldeletionPathogenicGRCh37Chr 17, 29660770: 29662293
91NF1NM_000267.3(NF1): c.5750-374_5944-176deldeletionPathogenicGRCh37Chr 17, 29661482: 29663175
92NF1NM_000267.3(NF1): c.5750-1748_6184delinsCTAindelPathogenicGRCh37Chr 17, 29660108: 29663752
93NF1NM_000267.3(NF1): c.5749+6_6858+633delins130indelPathogenicGRCh37Chr 17, 29657522: 29666456
94NF1NM_000267.3(NF1): c.5749+189_6999+1035deldeletionPathogenicGRCh37Chr 17, 29657705: 29668698
95NF1NM_000267.3(NF1): c.5943+265_7000-999delins15indelPathogenicGRCh37Chr 17, 29662314: 29669028
96NF1NM_000267.3(NF1): c.5943+448_7127-414deldeletionPathogenicGRCh37Chr 17, 29662497: 29675724
97NF1NM_000267.3(NF1): c.7000-499_7908-479deldeletionPathogenicGRCh37Chr 17, 29669528: 29685019
98NF1NM_000267.3(NF1): c.7258+383_7862deldeletionPathogenicGRCh37Chr 17, 29676652: 29684342
99NF1NM_000267.3(NF1): c.7395-600_7552+735deldeletionPathogenicGRCh37Chr 17, 29678675: 29680167
100NF1NM_000267.3: c.7566_8314+3321_delinsCGCCACGGCinsertionPathogenicChr na, -1: -1
101NF1NM_000267.3(NF1): c.7884_8315-5528deldeletionPathogenicGRCh37Chr 17, 29684364: 29695503
102NF1NM_000267.3(NF1): c.61-6522_204+1022dupduplicationPathogenicGRCh37Chr 17, 29476479: 29484166
103NF1NM_000267.3(NF1): c.289-1171_888+1963dupduplicationPathogenicGRCh38Chr 17, 31162015: 31184628
104NF1NM_000267.3(NF1): c.1393-1905_2251+85dupduplicationPathogenicGRCh37Chr 17, 29539564: 29553787
105NF1NM_000267.3(NF1): c.1527+443_3709-761dupduplicationPathogenicGRCh37Chr 17, 29542046: 29561868
106NF1NM_000267.3(NF1): c.2252-70_2326-39dupduplicationPathogenicGRCh37Chr 17, 29554166: 29554502
107NF1NM_000267.3(NF1): c.2851-151_2990+121dupduplicationPathogenicGRCh37Chr 17, 29556702: 29557113
108NF1NM_000267.3(NF1): c.3496+57_4772+2639dupduplicationPathogenicGRCh37Chr 17, 29559956: 29594996
109NF1NM_000267.3(NF1): c.4773-1597_7395-685dupduplicationPathogenicGRCh37Chr 17, 29651241: 29678590
110NF1NM_000267.3(NF1): c.7907+149_8097+723dupduplicationPathogenicGRCh37Chr 17, 29684536: 29686756
111NF1NM_000267.3(NF1): c.1094C> A (p.Ser365Ter)SNVPathogenicrs864622107GRCh38Chr 17, 31201068: 31201068
112NF1NM_000267.3(NF1): c.4537C> T (p.Arg1513Ter)SNVPathogenicrs760703505GRCh37Chr 17, 29588751: 29588751
113NF1NM_000267.3(NF1): c.3975-2A> GSNVPathogenicrs864622431GRCh38Chr 17, 31248982: 31248982
114NF1NM_000267.3(NF1): c.5458C> T (p.Gln1820Ter)SNVPathogenicrs786203570GRCh37Chr 17, 29654769: 29654769
115NF1NM_000267.3(NF1): c.5205+5G> ASNVPathogenicrs864622551GRCh37Chr 17, 29653275: 29653275
116NF1NM_000267.3(NF1): c.7096_7101delAACTTT (p.Asn2366_Phe2367del)deletionPathogenicrs864622639GRCh38Chr 17, 31343105: 31343110
117NF1NM_000267.3(NF1): c.4368-?_5943+?deldeletionPathogenicChr na, -1: -1
118NF1NM_001042492.2(NF1): c.5305C> T (p.Arg1769Ter)SNVPathogenicrs876657714GRCh37Chr 17, 29654553: 29654553
119NF1NM_000267.3(NF1): c.6791dupA (p.Tyr2264Terfs)duplicationPathogenicrs876657715GRCh38Chr 17, 31338738: 31338738
120NF1NM_001042492.2(NF1): c.1318C> T (p.Arg440Ter)SNVPathogenicrs778405030GRCh37Chr 17, 29533315: 29533315
121NF1NM_001042492.2(NF1): c.3113+2T> GSNVLikely pathogenic, Pathogenicrs876658997GRCh37Chr 17, 29557402: 29557402
122NF1NM_000267.3(NF1): c.-383-?_*3522+?deldeletionPathogenicChr na, -1: -1
123NF1NM_000267.3(NF1): c.1381C> T (p.Arg461Ter)SNVPathogenicrs878853865GRCh38Chr 17, 31206360: 31206360
124NF1NM_000267.3(NF1): c.2352G> A (p.Trp784Ter)SNVPathogenicrs199474778GRCh38Chr 17, 31227549: 31227549
125NF1NM_000267.3(NF1): c.2409+2delTdeletionPathogenicrs878853875GRCh38Chr 17, 31227608: 31227608
126NF1NM_000267.3(NF1): c.2604dupT (p.Pro869Serfs)duplicationPathogenicrs878853877GRCh37Chr 17, 29556237: 29556237
127NF1NM_000267.3(NF1): c.3064delA (p.Met1022Terfs)deletionPathogenicrs878853881GRCh37Chr 17, 29557351: 29557351
128NF1NM_000267.3(NF1): c.3565C> T (p.Gln1189Ter)SNVPathogenicrs878853884GRCh38Chr 17, 31233070: 31233070
129NF1NM_000267.3(NF1): c.3826C> T (p.Arg1276Ter)SNVPathogenicrs199474742GRCh37Chr 17, 29562746: 29562746
130NF1NM_000267.3(NF1): c.3897delA (p.Lys1299Asnfs)deletionPathogenicrs878853890GRCh37Chr 17, 29562962: 29562962
131NF1NM_000267.3(NF1): c.397delG (p.Glu133Asnfs)deletionPathogenicrs878853891GRCh37Chr 17, 29490312: 29490312
132NF1NM_000267.3(NF1): c.4255A> G (p.Lys1419Glu)SNVPathogenicrs199474790GRCh38Chr 17, 31258488: 31258488
133NF1NM_000267.3(NF1): c.4306A> G (p.Lys1436Glu)SNVPathogenicrs878853893GRCh38Chr 17, 31259068: 31259068
134NF1NM_000267.3(NF1): c.4420dupA (p.Ser1474Lysfs)duplicationPathogenicrs878853896GRCh37Chr 17, 29587439: 29587439
135NF1NM_000267.3(NF1): c.5608C> T (p.Gln1870Ter)SNVPathogenicrs878853904GRCh37Chr 17, 29657375: 29657375
136NF1NM_000267.3(NF1): c.649G> T (p.Glu217Ter)SNVPathogenicrs878853909GRCh38Chr 17, 31181484: 31181484
137NF1NM_000267.3(NF1): c.7206_7207delCA (p.His2402Glnfs)deletionPathogenicrs878853913GRCh38Chr 17, 31349199: 31349200
138NF1NM_000267.3(NF1): c.7518delG (p.Gln2507Asnfs)deletionPathogenicrs878853917GRCh37Chr 17, 29679398: 29679398
139NF1NM_000267.3(NF1): c.7868dupC (p.Glu2624Argfs)duplicationPathogenicrs878853918GRCh37Chr 17, 29684348: 29684348
140NF1NM_000267.3(NF1): c.889-2A> GSNVPathogenicrs878853922GRCh37Chr 17, 29527438: 29527438
141NF2NM_000268.3(NF2): c.-443-?_*3798+?deldeletionPathogenicChr na, -1: -1
142NF2NM_000268.3(NF2): c.1627A> T (p.Lys543Ter)SNVPathogenicrs878853925GRCh37Chr 22, 30077480: 30077480
143NF1NM_000267.3(NF1): c.129_130ins568 (p.?)insertionPathogenicGRCh38Chr 17, 31156051: 31156052
144NF1NM_000267.3(NF1): c.4168C> T (p.Leu1390Phe)SNVLikely pathogenic, Pathogenicrs199474789GRCh37Chr 17, 29585419: 29585419
145NF2NM_000268.3(NF2): c.1079T> C (p.Leu360Pro)SNVPathogenicrs74315492GRCh37Chr 22, 30067894: 30067894
146NF2NM_000268.3(NF2): c.240+1G> TSNVPathogenicrs587776562GRCh37Chr 22, 30032866: 30032866
147NF2NM_000268.3(NF2): c.1604T> C (p.Leu535Pro)SNVPathogenicrs74315493GRCh37Chr 22, 30077457: 30077457
148NF2NM_000268.3(NF2): c.1613A> C (p.Gln538Pro)SNVPathogenicrs74315494GRCh37Chr 22, 30077466: 30077466
149NF2NM_000268.3(NF2): c.286_288delTTC (p.Phe96del)deletionPathogenicrs121434260GRCh37Chr 22, 30035124: 30035126
150NF2NM_000268.3(NF2): c.544G> T (p.Glu182Ter)SNVPathogenicrs74315495GRCh37Chr 22, 30051610: 30051610
151NF2NM_000268.3(NF2): c.784C> T (p.Arg262Ter)SNVPathogenicrs74315496GRCh37Chr 22, 30057302: 30057302
152NF2NM_000268.3(NF2): c.958C> T (p.Gln320Ter)SNVPathogenicrs74315497GRCh37Chr 22, 30064394: 30064394
153NF2NM_000268.3(NF2): c.1021C> T (p.Arg341Ter)SNVPathogenicrs74315499GRCh37Chr 22, 30067836: 30067836
154NF2NM_000268.3(NF2): c.1219C> T (p.Gln407Ter)SNVPathogenicrs74315501GRCh37Chr 22, 30069354: 30069354
155NF2NM_000268.3(NF2): c.1387G> T (p.Glu463Ter)SNVPathogenicrs74315503GRCh37Chr 22, 30070871: 30070871
156NF2NM_000268.3(NF2): c.1396C> T (p.Arg466Ter)SNVPathogenicrs74315504GRCh37Chr 22, 30070880: 30070880
157NF2NM_000268.3(NF2): c.1579G> T (p.Glu527Ter)SNVPathogenicrs74315505GRCh37Chr 22, 30077432: 30077432
158NF2NM_000268.3(NF2): c.185T> C (p.Phe62Ser)SNVPathogenicrs121434261GRCh37Chr 22, 30032810: 30032810
159NF1NF1, ALU INSinsertionPathogenicChr na, -1: -1
160NF1NF1, 5-BP DELdeletionPathogenicChr na, -1: -1
161NF1NM_001042492.2(NF1): c.5858T> C (p.Leu1953Pro)SNVPathogenicrs199474792GRCh37Chr 17, 29661901: 29661901
162NF1NM_000267.3(NF1): c.5845A> T (p.Arg1949Ter)SNVPathogenicrs267606595GRCh37Chr 17, 29661951: 29661951
163NF1NM_000267.3(NF1): c.4267A> G (p.Lys1423Glu)SNVPathogenicrs137854550GRCh37Chr 17, 29585518: 29585518
164NF1NM_000267.3(NF1): c.5448dupC (p.Ser1817Leufs)duplicationPathogenicrs267606596GRCh37Chr 17, 29654759: 29654759
165NF1NM_000267.3(NF1): c.5465_5466insT (p.Lys1823Glnfs)insertionPathogenicrs267606597GRCh37Chr 17, 29654776: 29654777
166NF1NM_000267.3(NF1): c.6427C> A (p.Leu2143Met)SNVPathogenicrs137854551GRCh37Chr 17, 29664448: 29664448
167NF1NM_000267.3(NF1): c.6511T> A (p.Tyr2171Asn)SNVPathogenicrs267606598GRCh37Chr 17, 29664532: 29664532
168NF1NM_000267.3(NF1): c.5839C> T (p.Arg1947Ter)SNVPathogenicrs137854552GRCh37Chr 17, 29661945: 29661945
169NF1NM_000267.3(NF1): c.4084C> T (p.Arg1362Ter)SNVPathogenicrs137854560GRCh37Chr 17, 29576111: 29576111
170NF1NM_000267.3(NF1): c.3113+1G> ASNVPathogenicrs267606599GRCh37Chr 17, 29557401: 29557401
171NF1NM_001042492.2(NF1): c.1541_1542delAG (p.Gln514Argfs)deletionPathogenicrs267606600GRCh37Chr 17, 29546036: 29546037
172NF1NM_000267.3(NF1): c.3104T> G (p.Met1035Arg)SNVPathogenicrs137854553GRCh37Chr 17, 29557391: 29557391
173NF1NM_000267.3(NF1): c.4173A> T (p.Arg1391Ser)SNVPathogenicrs137854554GRCh37Chr 17, 29585424: 29585424
174NF1NM_000267.3(NF1): c.1642-8A> GSNVPathogenicrs267606602GRCh37Chr 17, 29548860: 29548860
175NF1NM_000267.3(NF1): c.3827G> C (p.Arg1276Pro)SNVPathogenicrs137854556GRCh37Chr 17, 29562747: 29562747
176NF1NM_000267.3(NF1): c.1466A> G (p.Tyr489Cys)SNVPathogenicrs137854557GRCh37Chr 17, 29541542: 29541542
177NF1NM_000267.3(NF1): c.1523T> C (p.Leu508Pro)SNVPathogenicrs137854558GRCh37Chr 17, 29541599: 29541599
178NF1NM_000267.3(NF1): c.1260+1G> ASNVPathogenicrs267606603GRCh37Chr 17, 29528504: 29528504
179NF1NM_000267.3(NF1): c.4021C> T (p.Gln1341Ter)SNVPathogenicrs137854559GRCh37Chr 17, 29576048: 29576048
180NF1NM_000267.3(NF1): c.5944-5A> GSNVPathogenicrs267606604GRCh37Chr 17, 29663346: 29663346
181NF1NF1, DELdeletionPathogenicChr na, -1: -1
182NF1NM_001042492.2(NF1): c.3721C> T (p.Arg1241Ter)SNVPathogenicrs137854562GRCh37Chr 17, 29562641: 29562641
183NF1NM_000267.3(NF1): c.5406dupT (p.Ile1803Tyrfs)duplicationPathogenicrs267606605GRCh37Chr 17, 29654717: 29654717
184NF1NM_000267.3(NF1): c.2970_2972delAAT (p.Met992del)deletionPathogenicrs267606606GRCh37Chr 17, 29556972: 29556974
185NF1NF1, 1-BP DEL, 3775TdeletionPathogenicChr na, -1: -1
186NF1NM_000267.3(NF1): c.1070T> C (p.Leu357Pro)SNVPathogenicrs137854563GRCh37Chr 17, 29528062: 29528062
187NF1NF1, 1-BP DEL, 4071CdeletionPathogenicChr na, -1: -1
188NF1NM_000267.3(NF1): c.3728T> C (p.Leu1243Pro)SNVPathogenicrs137854564GRCh37Chr 17, 29562648: 29562648
189NF1NM_000267.3(NF1): c.5710G> T (p.Glu1904Ter)SNVPathogenicrs137854565GRCh37Chr 17, 29657477: 29657477
190NF1NM_000267.3(NF1): c.2531T> G (p.Leu844Arg)SNVPathogenicrs137854566GRCh37Chr 17, 29556164: 29556164
191NF1NF1, IVS27DS, G-C, +1SNVPathogenicChr na, -1: -1
192NF1NM_000267.3(NF1): c.574C> T (p.Arg192Ter)SNVPathogenicrs397514641GRCh37Chr 17, 29497003: 29497003
193NF1NM_000267.3(NF1): c.1595T> C (p.Leu532Pro)SNVPathogenicrs199474737GRCh37Chr 17, 29546090: 29546090
194NF1NM_001042492.2(NF1): c.1885G> A (p.Gly629Arg)SNVPathogenicrs199474738GRCh37Chr 17, 29552152: 29552152
195NF1NM_001042492.2(NF1): c.2288T> C (p.Leu763Pro)SNVLikely pathogenic, Pathogenicrs199474762GRCh37Chr 17, 29554272: 29554272
196NF1NM_001042492.2(NF1): c.3827G> A (p.Arg1276Gln)SNVPathogenicrs137854556GRCh37Chr 17, 29562747: 29562747

Copy number variations for Neurofibromatosis, Type 2 from CNVD:

6 (show top 50)    (show all 71)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1107543171590000022100000MicrodeletionNeurofibromatosis
2108747172220000078774742DeletionNeurofibromatosis
3108749172220000078774742Deletion duplicatio nNeurofibromatosis
4108858172320000028800000Deletion or duplicat ionNF1Neurofibromatosis
5108865172320000028800000MicrodeletionAK3P1bNeurofibromatosis type 1
6108866172320000028800000MicrodeletionATAD5Neurofibromatosis type 1
7108868172320000028800000MicrodeletionC17orf42Neurofibromatosis type 1
8108869172320000028800000MicrodeletionC17orf79Neurofibromatosis type 1
9108870172320000028800000MicrodeletionCENTA2Neurofibromatosis type 1
10108871172320000028800000MicrodeletionCRLF3Neurofibromatosis type 1
11108872172320000028800000MicrodeletionDPRXP4Neurofibromatosis type 1
12108873172320000028800000MicrodeletionEVI2ANeurofibromatosis type 1
13108874172320000028800000MicrodeletionEVI2BNeurofibromatosis type 1
14108875172320000028800000MicrodeletionLOC646013Neurofibromatosis type 1
15108876172320000028800000MicrodeletionLOC646021Neurofibromatosis type 1
16108877172320000028800000MicrodeletionLOC646037Neurofibromatosis type 1
17108878172320000028800000MicrodeletionLRRC37BNeurofibromatosis type 1
18108879172320000028800000MicrodeletionLRRC37B2Neurofibromatosis type 1
19108880172320000028800000MicrodeletionMIRN193ANeurofibromatosis type 1
20108881172320000028800000MicrodeletionMIRN365-2Neurofibromatosis type 1
21108882172320000028800000MicrodeletionNF1Neurofibromatosis type 1
22108883172320000028800000MicrodeletionNF1Neurofibromatosis type 1
23108884172320000028800000MicrodeletionNF1Neurofibromatosis type 1
24108885172320000028800000MicrodeletionNF1Neurofibromatosis type 1
25108886172320000028800000MicrodeletionOMGNeurofibromatosis type 1
26108887172320000028800000MicrodeletionRAB11FIP4Neurofibromatosis type 1
27108888172320000028800000MicrodeletionRNF135Neurofibromatosis type 1
28108889172320000028800000MicrodeletionSUZ12Neurofibromatosis type 1
29108890172320000028800000MicrodeletionSUZ12Neurofibromatosis type 1
30108891172320000028800000MicrodeletionSUZ12PNeurofibromatosis type 1
31108892172320000028800000MicrodeletionSUZ12PNeurofibromatosis type 1
32108893172320000028800000MicrodeletionUTP6Neurofibromatosis type 1
33108894172320000028800000Microdeletion or mic roduplicationNF1Neurofibromatosis type 1
34109393172580000031800000DeletionNeurofibromatosis
35109395172580000031800000DeletionNF1Neurofibromatosis type 1
36109408172580000031800000Copy numberNF1Neurofibromatosis type 1
37109504172644612026728821MicrodeletionNF1Neurofibromatosis type 1
38109505172644612026728821MicrodeletionNF1Neurofibromatosis type 1
39109506172644612026728821MicrodeletionNF1Neurofibromatosis type 1
40109522172657621426734130DeletionEVI2ANeurofibromatosis type 1
41109523172657621426734130DeletionEVI2BNeurofibromatosis type 1
42109524172657621426734130DeletionNF1Neurofibromatosis type 1
43109525172657621426734130DeletionOMGNeurofibromatosis type 1
44109526172657621426734130DeletionRAB11FIP4Neurofibromatosis type 1
45109530172661148626611711DeletionNeurofibromatosis
46109531172661278126613078DeletionNeurofibromatosis
47109532172661411226614421DeletionNeurofibromatosis
48109533172661628726616583DeletionNeurofibromatosis
49109534172664225428641850DeletionNeurofibromatosis
50109539172664660626646625DeletionNeurofibromatosis

Expression for genes affiliated with Neurofibromatosis, Type 2

About this section
Search GEO for disease gene expression data for Neurofibromatosis, Type 2.

Pathways for genes affiliated with Neurofibromatosis, Type 2

About this section

Pathways related to Neurofibromatosis, Type 2 according to GeneCards Suite gene sharing:

(show all 30)
idSuper pathwaysScoreTop Affiliating Genes
110.1NF1, PTPN11
29.9NF1, RASA1, RASA2
3
Show member pathways
9.9NF1, RASA1, RASA2
49.9EZR, MSN, RDX
5
Show member pathways
9.9EZR, MSN, RDX
6
Show member pathways
9.9SDHB, SDHC, SDHD
79.8HRAS, RASA1, RET
89.8HRAS, PTPN11, RASA1
9
Show member pathways
9.8HRAS, PTPN11, RASA1
10
Show member pathways
9.8HRAS, PTPN11, RASA1
11
Show member pathways
9.7HRAS, KIT, RET
129.7HRAS, NF1, NF2, PDGFRA
139.7EZR, HRAS, NF1, RASA1
14
Show member pathways
9.7HRAS, NF1, RASA1, RASA2
15
Show member pathways
9.6HRAS, NF1, PTPN11, RASA1
169.6HRAS, PTPN11, RASA1, SLC9A3R1
17
Show member pathways
9.6HRAS, PDGFRA, PTPN11, RASA1
189.5HRAS, PTPN11, RASA1, RET
199.5KIT, PDGFRA, RET, SLC9A3R1
20
Show member pathways
9.5EZR, MSN, RDX, SPTBN1
21
Show member pathways
9.5HRAS, KIT, PTPN11, RASA1
229.5HRAS, KIT, PDGFRA, RET
239.5HRAS, KIT, PDGFRA, RET
24
Show member pathways
9.4HRAS, KIT, PDGFRA, PTPN11
259.4HRAS, NF1, PDGFRA, RASA1, RASA2
26
Show member pathways
9.4EZR, HRAS, MSN, PDGFRA, RDX
279.3EZR, HRAS, MSN, PTPN11, RDX
28
Show member pathways
9.1EZR, HRAS, KIT, MSN, PDGFRA, RDX
29
Show member pathways
8.9HRAS, KIT, NF1, PDGFRA, PTPN11, RASA1
30
Show member pathways
7.7EZR, HRAS, KIT, MSN, NF1, PDGFRA

GO Terms for genes affiliated with Neurofibromatosis, Type 2

About this section

Cellular components related to Neurofibromatosis, Type 2 according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1cell tipGO:005128610.9EZR, RDX
2intrinsic component of the cytoplasmic side of the plasma membraneGO:003123510.7NF1, RASA1, RASA2
3mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone)GO:000574910.6SDHB, SDHC, SDHD
4microvillus membraneGO:003152810.6EZR, MSN, SLC9A3R1
5respiratory chain complex IIGO:004527310.5SDHB, SDHC
6axolemmaGO:003067310.5EPB41L3, SPTBN1
7membrane raftGO:004512110.5EZR, NF2, RET, SLC9A3R1
8cell peripheryGO:007194410.5EZR, MSN, RDX, SLC9A3R1
9microvillusGO:000590210.4EZR, MSN, RDX, SLC9A3R1
10apical part of cellGO:004517710.3EZR, MSN, NF2, RDX, SLC9A3R1
11filopodiumGO:003017510.3EZR, MSN, NF2, RDX, SLC9A3R1
12extrinsic component of membraneGO:001989810.1EPB41L3, EZR, MSN, NF2, RDX
13uropodGO:000193110.0EZR, MSN
14perinuclear region of cytoplasmGO:004847110.0EZR, HRAS, MSN, NF2, RASA2, SLC9A3R1
15ruffleGO:00017269.8EZR, NF2, RASA1, RDX, SLC9A3R1
16plasma membraneGO:00058867.5EPB41L3, EZR, HRAS, KIT, MSN, NF2
17cytoplasmGO:00057377.5EPB41L3, EZR, HRAS, KIT, MSN, NF1

Biological processes related to Neurofibromatosis, Type 2 according to GeneCards Suite gene sharing:

(show all 30)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.8NF1, RET
2membrane to membrane dockingGO:002261410.8EZR, MSN
3cellular response to thyroid hormone stimulusGO:009706710.7KIT, RDX
4protein kinase A signalingGO:001073710.7EZR, RDX
5negative regulation of cell-matrix adhesionGO:000195310.7NF1, NF2, RASA1
6negative regulation of cell migrationGO:003033610.7NF1, NF2, SLC9A3R1
7actin filament cappingGO:005169310.7RDX, SPTBN1
8negative regulation of Ras protein signal transductionGO:004658010.6NF1, RASA1, RASA2
9establishment of protein localization to plasma membraneGO:009000210.6EZR, RDX, SLC9A3R1
10microvillus assemblyGO:003003310.6EZR, RDX, SLC9A3R1
11cytoskeletal anchoring at plasma membraneGO:000701610.6EPB41L3, EZR
12establishment of endothelial barrierGO:006102810.6EZR, MSN, RDX
13establishment of epithelial cell apical/basal polarityGO:004519810.6EZR, MSN, SLC9A3R1
14positive regulation of phospholipase C activityGO:001086310.6KIT, PDGFRA
15positive regulation of cellular protein catabolic processGO:190336410.6EZR, MSN, RDX
16positive regulation of early endosome to late endosome transportGO:200064310.6EZR, MSN, RDX
17gland morphogenesisGO:002261210.6EZR, MSN, SLC9A3R1
18ephrin receptor signaling pathwayGO:004801310.5HRAS, PTPN11, RASA1
19positive regulation of protein localization to early endosomeGO:190296610.5EZR, MSN, RDX
20phosphatidylinositol phosphorylationGO:004685410.4KIT, PDGFRA, PTPN11
21regulation of organelle assemblyGO:190211510.4EZR, MSN, RDX
22phosphatidylinositol-mediated signalingGO:004801510.2EZR, KIT, PDGFRA, PTPN11
23regulation of cell sizeGO:000836110.2EZR, MSN, RDX, SLC9A3R1
24regulation of phosphatidylinositol 3-kinase signalingGO:001406610.1KIT, PDGFRA, PTPN11
25positive regulation of cell migrationGO:003033510.0HRAS, KIT, PDGFRA, RDX, RET
26tricarboxylic acid cycleGO:00060999.9SDHB, SDHC, SDHD
27positive regulation of gene expressionGO:00106289.7EZR, HRAS, KIT, MSN, RDX, RET
28regulation of cell shapeGO:00083609.3EPB41L3, EZR, KIT, MSN, RASA1, RDX
29MAPK cascadeGO:00001659.3HRAS, KIT, NF1, PDGFRA, RASA1, RASA2
30positive regulation of GTPase activityGO:00435479.1HRAS, KIT, NF1, PDGFRA, RASA1, RASA2

Molecular functions related to Neurofibromatosis, Type 2 according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1succinate dehydrogenase activityGO:000010410.5SDHC, SDHD
2electron carrier activityGO:000905510.5SDHB, SDHC, SDHD
3cell adhesion molecule bindingGO:005083910.5EZR, MSN, PTPN11
4phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.4KIT, PDGFRA, PTPN11
5ubiquinone bindingGO:004803910.1SDHB, SDHD
6protein domain specific bindingGO:001990410.1EZR, NF2, PTPN11, RDX, SLC9A3R1
7transmembrane receptor protein tyrosine kinase activityGO:00047149.9KIT, PDGFRA, RET
8Ras guanyl-nucleotide exchange factor activityGO:00050889.8KIT, PDGFRA, RET, SPTBN1
9actin bindingGO:00037799.6EPB41L3, EZR, MSN, NF2, RDX, SPTBN1

Sources for Neurofibromatosis, Type 2

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet